{"id":52495,"date":"2021-04-06T07:13:00","date_gmt":"2021-04-06T07:13:00","guid":{"rendered":"https:\/\/www.verificat.cat\/covaxin-fontionne\/"},"modified":"2021-04-06T07:13:00","modified_gmt":"2021-04-06T07:13:00","slug":"covaxin-fontionne","status":"publish","type":"post","link":"https:\/\/www.verificat.cat\/fr\/covaxin-fontionne\/","title":{"rendered":"Covaxin"},"content":{"rendered":"<p><br \/>\n<\/p>\n<p>Covaxin est le premier vaccin 100 % indien, mis au point par l&rsquo;entreprise de biotechnologie<a href=\"https:\/\/www.bharatbiotech.com\/index.html\" target=\"_blank\" rel=\"noopener\"> Bharat Biotech<\/a>, en collaboration avec le Conseil indien de recherche m&eacute;dicale et l&rsquo;Institut national de virologie. Sa formule se fonde sur un<a href=\"https:\/\/www.bharatbiotech.com\/covaxin.html\" target=\"_blank\" rel=\"noopener\"> virus inactiv&eacute;<\/a>. Elle fait appel &agrave; une<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7189890\/\" target=\"_blank\" rel=\"noopener\"> version morte du virus<\/a> &agrave; l&rsquo;origine de la maladie, qui ne peut donc pas contaminer, mais peut provoquer une r&eacute;ponse immunitaire.<\/p>\n<p>Les essais cliniques ont d&eacute;but&eacute; en<a href=\"https:\/\/www.bharatbiotech.com\/covaxin.html\" target=\"_blank\" rel=\"noopener\"> juillet 2020<\/a> et les<a href=\"https:\/\/www.bharatbiotech.com\/images\/press\/covaxin-phase3-efficacy-results.pdf\" target=\"_blank\" rel=\"noopener\"> r&eacute;sultats<\/a> ont &eacute;t&eacute; publi&eacute;s le 3 mars 2021. Au total,<a href=\"https:\/\/www.bharatbiotech.com\/images\/press\/covaxin-phase3-efficacy-results.pdf\" target=\"_blank\" rel=\"noopener\"> 25 800 personnes<\/a> ont particip&eacute; &agrave; la phase III, et les r&eacute;sultats ont donn&eacute; une<a href=\"https:\/\/www.bharatbiotech.com\/images\/press\/covaxin-phase3-efficacy-results.pdf\" target=\"_blank\" rel=\"noopener\"> efficacit&eacute; de 81 %<\/a>.<\/p>\n<p>Covaxin consiste en<a href=\"https:\/\/www.bharatbiotech.com\/covaxin.html\" target=\"_blank\" rel=\"noopener\"> deux doses<\/a> administr&eacute;es &agrave;<a href=\"https:\/\/www.bharatbiotech.com\/covaxin.html\" target=\"_blank\" rel=\"noopener\"> 28 jours d&rsquo;intervalle<\/a>, et<a href=\"https:\/\/www.bharatbiotech.com\/covaxin.html\" target=\"_blank\" rel=\"noopener\"> pr&egrave;s d&rsquo;une dizaine de pays<\/a> asiatiques l&rsquo;utilisent pour immuniser leur population.<\/p>\n<p>Les<a href=\"https:\/\/www.bharatbiotech.com\/images\/covaxin\/covaxin-fact-sheet.pdf\" target=\"_blank\" rel=\"noopener\"> effets secondaires les plus fr&eacute;quents<\/a>, d&rsquo;apr&egrave;s Bharat Biotech, concernent la douleur, l&rsquo;inflammation et les rougeurs dans la zone de l&rsquo;injection, les picotements, les &eacute;ruptions cutan&eacute;es, les maux de t&ecirc;te, la fi&egrave;vre, le mal-&ecirc;tre g&eacute;n&eacute;ral, les naus&eacute;es et les vomissements. Les r&eacute;actions allergiques graves peuvent se produire en de tr&egrave;s rares occasions, toujours selon les donn&eacute;es de l&rsquo;entreprise.<\/p>\n<p><a href=\"https:\/\/www.nationalheraldindia.com\/national\/this-is-how-india-has-planned-covishield-covaxin-storage\" target=\"_blank\" rel=\"noopener\">Covaxin<\/a> se conserve &agrave; une temp&eacute;rature moyenne comprise entre 2 et 8&deg;C.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Covaxin est le premier vaccin 100 % indien, mis au  [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[170],"tags":[209],"class_list":["post-52495","post","type-post","status-publish","format-standard","hentry","category-non-classifiee","tag-vaccines-fr","vc-legacy-post"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.verificat.cat\/fr\/wp-json\/wp\/v2\/posts\/52495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.verificat.cat\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.verificat.cat\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.verificat.cat\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.verificat.cat\/fr\/wp-json\/wp\/v2\/comments?post=52495"}],"version-history":[{"count":0,"href":"https:\/\/www.verificat.cat\/fr\/wp-json\/wp\/v2\/posts\/52495\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.verificat.cat\/fr\/wp-json\/wp\/v2\/media?parent=52495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.verificat.cat\/fr\/wp-json\/wp\/v2\/categories?post=52495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.verificat.cat\/fr\/wp-json\/wp\/v2\/tags?post=52495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}